Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw ...

Anlotinib plus chemotherapy demonstrated similar efficacy as bevacizumab plus chemotherapy for certain patients with ...

A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Phase 3 trial evaluates encorafenib, cetuximab, and chemotherapy in untreated BRAF V600E-mutant metastatic colorectal cancer, ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall ...